Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-f38fd388d9d557d533fdef41848d682d"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-f38fd388d9d557d533fdef41848d682d"/>
<resource>
<Composition>
<id value="composition-en-f38fd388d9d557d533fdef41848d682d"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-f38fd388d9d557d533fdef41848d682d"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-f38fd388d9d557d533fdef41848d682d</b></p><a name="composition-en-f38fd388d9d557d533fdef41848d682d"> </a><a name="hccomposition-en-f38fd388d9d557d533fdef41848d682d"> </a><a name="composition-en-f38fd388d9d557d533fdef41848d682d-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/20/1424/001 - 011</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - nustendi</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/20/1424/001 - 011"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mpf38fd388d9d557d533fdef41848d682d"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - nustendi"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What Nustendi is and what it is used for</li><li>What you need to know before you take Nustendi</li><li>How to take Nustendi</li><li>Possible side effects</li><li>How to store Nustendi</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What nustendi is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What nustendi is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Nustendi is and how it works</p><p>Nustendi is a medicine that lowers levels of bad cholesterol (also called LDL-cholesterol ), a type of fat, in the blood.</p><p>Nustendi contains two active substances, which reduce your cholesterol in two ways:</p><ul><li>bempedoic acid decreases the production of cholesterol in the liver and increases the removal of LDL-cholesterol from the blood;</li><li>ezetimibe works in your bowel by reducing the amount of cholesterol absorbed from food.</li></ul><p>What Nustendi is used for</p><p>Nustendi is given to adults with primary hypercholesterolaemia or mixed dyslipidaemia, which are conditions that cause a high cholesterol level in the blood. It is given in addition to a cholesterol- lowering diet.</p><p>Nustendi is given:</p><ul><li>if you have been using a statin (such as simvastatin, a commonly used medicine that treats high cholesterol) together with ezetimibe and this does not lower your LDL-cholesterol sufficiently;</li><li>if you have been using ezetimibe and this does not lower your LDL-cholesterol sufficiently;</li><li>to replace bempedoic acid and ezetimibe if you have been using these medicines as separate tablets.</li></ul></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take nustendi"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text
value="2. What you need to know before you take nustendi"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not take Nustendi:</p><ul><li>if you are allergic to bempedoic acid, ezetimibe or any of the other ingredients of this medicine (listed in section 6);</li><li>if you are pregnant;</li><li>if you are breast-feeding;</li><li>if you take more than 40 mg of simvastatin daily (another medicine used to lower cholesterol);</li><li>with a statin if you currently have liver problems.</li><li>Nustendi contains ezetimibe. When Nustendi is given together with a statin, you should also read the information relating to ezetimibe in the Package leaflet of that specific statin.</li></ul><p>Warnings and precautions</p><p>Talk to your doctor or pharmacist before taking Nustendi:</p><ul><li>if you ever had gout;</li><li>if you have severe kidney problems;</li><li>if you have moderate or severe liver problems. Nustendi is not recommended in this case.</li></ul><p>Your doctor should do a blood test before you start taking Nustendi with a statin. This is to check how well your liver is working.</p><p>Children and adolescents</p><p>Do not give Nustendi to children and adolescents under 18 years of age. The use of Nustendi has not been studied in this age group.</p><p>Other medicines and Nustendi</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. In particular, tell your doctor if you are taking medicine(s) with any of the following active substances:</p><ul><li>atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin (used to lower cholesterol and known as statins). The risk of muscle disease may increase when taking both a statin and Nustendi. Tell your doctor immediately about any unexplained muscle pain, tenderness or weakness.</li><li>bosentan (used to manage a condition called pulmonary artery hypertension).</li><li>fimasartan (used to treat high blood pressure and heart failure).</li><li>asunaprevir, glecaprevir, grazoprevir, voxilaprevir (used to treat hepatitis C).</li><li>fenofibrate (also used to lower cholesterol). No information is available on the effects of using Nustendi with cholesterol-lowering medicines called fibrates.</li><li>ciclosporin (often used in organ transplant patients).</li><li>colestyramine (also used to lower cholesterol), because it affects the way ezetimibe works.</li><li>medicines to prevent blood clots, such as warfarin as well as acenocoumarol, fluindione, and phenprocoumon.</li></ul><p>Pregnancy and breast-feeding</p><p>Do not take this medicine if you are pregnant, trying to get pregnant, or think you may be pregnant, as there is a possibility that it could harm an unborn baby. If you get pregnant while taking this medicine, call your doctor immediately and stop taking Nustendi.</p><ul><li>Pregnancy Before starting treatment, you should confirm you are not pregnant and are using effective contraception, as advised by your doctor. If you use contraceptive pills and suffer from an episode of diarrhoea or vomiting that lasts more than 2 days, you must use an alternative method of contraception (e.g. condoms, diaphragm) for 7 days following resolution of symptoms.</li></ul><p>If, after you have started treatment with Nustendi, you decide that you would like to become pregnant, tell your doctor, as your treatment will need to be changed.</p><ul><li>Breast-feeding Do not take Nustendi if you are breast-feeding because it is not known if Nustendi passes into milk.</li></ul><p>Driving and using machines</p><p>Nustendi has minor influence on the ability to drive and use machines.</p><p>However, some people may get dizzy after taking Nustendi. Avoid driving or using machines if you think your ability to react is reduced.</p><p>Nustendi contains lactose and sodium</p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p><p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially sodium- free .</p></div>
</text>
</section>
<section>
<title value="3. How to take nustendi"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take nustendi"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>The recommended dose is one tablet once daily.</p><p>If you are taking colestyramine, take Nustendi either at least 2 hours before or at least 4 hours after taking colestyramine.</p><p>Swallow the tablet whole with food or between meals.</p><p>If you take more Nustendi than you should</p><p>Contact your doctor or pharmacist immediately.</p><p>If you forget to take Nustendi</p><p>If you notice that you forgot:</p><ul><li>a dose late in a day, take the missed dose and take the next dose at your regular time the next day.</li><li>the previous day s dose, take your tablet at the regular time and do not make up for the forgotten dose. If you stop taking Nustendi</li></ul><p>Do not stop taking Nustendi without your doctor s permission as your cholesterol may rise again.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Contact your doctor immediately if you have any of the following serious side effects (frequencies are unknown):</p><ul><li>muscle pain or weakness</li><li>yellowish skin and eyes, abdominal pain, dark urine, swollen ankles, decreased appetite, and feeling tired that could be signs of liver problems</li><li>allergic reactions including rash and hives; raised red rash, sometimes with target-shaped lesions (erythema multiforme)</li><li>gallstones or inflammation of the gallbladder (which may cause abdominal pain, nausea, vomiting), inflammation of the pancreas often with severe abdominal pain</li><li>reduction in blood platelets, which may cause bruising/bleeding (thrombocytopenia)</li></ul><p>Other side effects can occur with the following frequencies:</p><p>Common (may affect up to 1 in 10 people)</p><ul><li>lower number of red blood cells (anaemia)</li><li>decreased haemoglobin (a protein in red blood cells that carries oxygen)</li><li>increased levels of uric acid in blood, gout</li><li>decreased appetite</li><li>dizziness, headache</li><li>high blood pressure</li><li>cough</li><li>constipation, diarrhoea, abdominal pain</li><li>nausea</li><li>dry mouth</li><li>abdominal bloating and gas, inflammation of the stomach lining (gastritis)</li><li>blood test results indicating liver abnormalities</li><li>muscle spasm, muscle pain, pain in shoulders, legs or arms, back pain, blood test showing raised creatine kinase (a laboratory test of muscle damage), muscle weakness, joint pain (arthralgia)</li><li>raised creatinine and blood urea nitrogen (laboratory tests of kidney function)</li><li>unusual tiredness or weakness</li></ul><p>Uncommon (may affect up to 1 in 100 people)</p><ul><li>hot flush</li><li>pain in the upper part of stomach, heartburn, indigestion</li><li>itching</li><li>swelling of the legs or hands</li><li>neck pain, chest pain, pain</li><li>decreased glomerular filtration rate (a measure of how well your kidneys are working)</li></ul><p>Not known (frequency cannot be estimated from available data)</p><ul><li>tingling sensation</li><li>depression</li><li>shortness of breath Reporting of side effects</li></ul><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store nustendi"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store nustendi"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the blister and carton after EXP. The expiry date refers to the last day of the month.</p><p>This medicine does not require any special temperature storage conditions. Store in the original package in order to protect from moisture.</p><p>Do not throw away any medicine via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Nustendi contains</p><ul><li>The active substances are bempedoic acid and ezetimibe. Each film-coated tablet contains 180 mg of bempedoic acid and 10 mg of ezetimibe.</li><li>The other ingredients are:</li></ul><ul><li>lactose monohydrate (see end of section 2 under Nustendi contains lactose and sodium )</li><li>microcrystalline cellulose (E460)</li><li>sodium starch glycolate (Type A grade) (see end of section 2 under Nustendi contains lactose and sodium )</li><li>hydroxypropyl cellulose (E463)</li><li>magnesium stearate (E470b)</li><li>silica, colloidal anhydrous (E551)</li><li>sodium laurilsulfate (E487) (see end of section 2 under Nustendi contains lactose and sodium )</li><li>povidone (K30) (E1201)</li><li>partially hydrolysed poly(vinyl alcohol) (E1203), talc (E553b), titanium dioxide (E171), Indigo Carmine Aluminium Lake (E132), glycerol monocaprylocaprate, Brilliant Blue FCF Aluminium Lake (E133)</li></ul><p>What Nustendi looks like and contents of the pack</p><p>Film-coated tablets are blue, oval, debossed with 818 on one side and ESP on the other side. Tablet dimensions: 15 mm 7 mm 5 mm.</p><p>Nustendi is supplied in plastic/aluminium blisters in cartons of 10, 14, 28, 30, 84, 90, 98 or 100 film- coated tablets or unit dose blisters in cartons of 10 x 1, 50 x 1, or 100 x 1 film-coated tablets.</p><p>Not all pack sizes may be marketed in your country. Marketing Authorisation Holder</p><p>Daiichi Sankyo Europe GmbH Zielstattstrasse 81379 Munich Germany</p><p>Manufacturer</p><p>Daiichi Sankyo Europe GmbH Luitpoldstrasse 1 85276 Pfaffenhofen Germany</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgi /Belgique/Belgien Daiichi Sankyo Belgium N.V.-S.A T l/Tel: +32-(0) 2 227 18 Lietuva Daiichi Sankyo Europe GmbH Tel: +49-(0) 89 7808 0</p><p>Daiichi Sankyo Europe GmbH .: +49-(0) 89 7808 0 Luxembourg/Luxemburg Daiichi Sankyo Belgium N.V.-S.A T l/Tel: +32-(0) 2 227 18 esk republika Zentiva, k.s. Tel: +420 267 241 Magyarorsz g Daiichi Sankyo Europe GmbH Tel.: +49-(0) 89 7808 0 Danmark Daiichi Sankyo Europe GmbH Tlf: +49-(0) 89 7808 0 Malta Daiichi Sankyo Europe GmbH Tel: +49-(0) 89 7808 0 Deutschland Daiichi Sankyo Deutschland GmbH Tel: +49-(0) 89 7808 0 Nederland Daiichi Sankyo Nederland B.V. Tel: +31-(0) 20 4 07 20 Eesti Daiichi Sankyo Europe GmbH Tel: +49-(0) 89 7808 0 Norge Daiichi Sankyo Europe GmbH Tlf: +49-(0) 89 7808 0</p><p>Daiichi Sankyo Europe GmbH : +49-(0) 89 7808 0 sterreich Daiichi Sankyo Austria GmbH Tel: +43 (0) 1 485 86 42 0 Espa a Daiichi Sankyo Espa a, S.A. Tel: +34 91 539 99 Polska Daiichi Sankyo Europe GmbH Tel.: +49-(0) 89 7808 0 France Daiichi Sankyo France S.A.S. T l: +33 (0) 1 55 62 14 Portugal Daiichi Sankyo Portugal, Unip. LDA Tel: +351 21 4232Hrvatska Daiichi Sankyo Europe GmbH Tel: +49-(0) 89 7808 0 Rom nia Daiichi Sankyo Europe GmbH Tel: +49-(0) 89 7808 0 Ireland Daiichi Sankyo Ireland Ltd Tel: +353-(0) 1 489 3Slovenija Daiichi Sankyo Europe GmbH Tel: +49-(0) 89 7808 0 sland Daiichi Sankyo Europe GmbH S mi: +49-(0) 89 7808 0 Slovensk republika Zentiva, a.s. Tel: +421 2 3918 3Italia Daiichi Sankyo Italia S.p.A. Tel: +39-06 85 2Suomi/Finland Daiichi Sankyo Europe GmbH Puh/Tel: +49-(0) 89 7808 0</p><p>Daiichi Sankyo Europe GmbH : +49-(0) 89 7808 0 Sverige Daiichi Sankyo Europe GmbH Tel: +49-(0) 89 7808 0 Latvija Daiichi Sankyo Europe GmbH Tel: +49-(0) 89 7808 0 United Kingdom (Northern Ireland) Daiichi Sankyo Europe GmbH Tel: +49-(0) 89 7808 0</p><p>This leaflet was last revised in {month YYYY}.</p><p>Other sources of information</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mpf38fd388d9d557d533fdef41848d682d"/>
<resource>
<MedicinalProductDefinition>
<id value="mpf38fd388d9d557d533fdef41848d682d"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mpf38fd388d9d557d533fdef41848d682d"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mpf38fd388d9d557d533fdef41848d682d</b></p><a name="mpf38fd388d9d557d533fdef41848d682d"> </a><a name="hcmpf38fd388d9d557d533fdef41848d682d"> </a><a name="mpf38fd388d9d557d533fdef41848d682d-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/20/1424/001 - 011</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Nustendi 180 mg/10 mg film-coated tablets</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/20/1424/001 - 011"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName value="Nustendi 180 mg/10 mg film-coated tablets"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
